Q&A: MD Anderson's Mendelsohn Discusses WIN Consortium's Effort to Advance Personalized Cancer Drugs
June 22, 2011
Q&A: MD Anderson's Mendelsohn Discusses WIN Consortium's Effort to Advance Personalized Cancer Drugs
Launched by the Institute Gustav Roussy in France and the University of Texas MD Anderson Cancer Center, the Worldwide Innovative Networking Consortium aims to help drugmakers change the way they develop drugs by focusing on treating diseases with common molecular features, rather than treating disease at an organ site.
Full-text access for premium subscribers only.
Existing premium subscribers login here.
New to GenomeWeb? Register here quickly.
New to GenomeWeb? Register here quickly.
Related Stories
- New Products: Agilent's HaloPlex Panels; Life Technologies' Oncomine NGS Power Tools
June 12, 2013 / Clinical Sequencing News - Asuragen Launches Cancer Panels Optimized for FFPE Tissue; Plans to Sell Proprietary Reagents
April 10, 2013 / Clinical Sequencing News - New Products: Illumina's TruSight Tumor Content; Ambry's Tumor Profiling Services; More
April 10, 2013 / Clinical Sequencing News - New Products: Life Tech's Ion AmpliSeq Panels
April 3, 2013 / Clinical Sequencing News - Fox Chase Debuts CancerCode-45 Test Based on Adapted Ion Torrent AmpliSeq Panel
January 16, 2013 / Clinical Sequencing News